SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is currently seeing intense debate as investors weigh aggressive institutional Ethereum accumulation against significant share price underperformance compared to broader crypto markets. Community sentiment is deeply polarized, with many retail traders expressing frustration over Tom Lee's leadership and dilution tactics while bulls continue to focus on the long-term potential of asset tokenization and upcoming clarity legislation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased volatility and investor attention following reports that Berkshire Hathaway has exited its entire position in the stock. While some investors express concern over this abrupt move by a major institutional holder, many in the community view the resulting dip as a potential buying opportunity, emphasizing the company's long-term operational strengths and its ongoing integration of AI into daily workflows.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for upcoming clinical data presentations at the AUA Annual Meeting, with the community focused on the durability of CAN-2409 and its potential as a practice-changing therapy. Discussions center on the stock's long-term value, with active debates occurring between bulls anticipating a premium acquisition and bears citing concerns over cash runway and timing.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors draw comparisons to high-growth semiconductor testing peers, citing its exposure to AI and EV chip demand. The community is actively discussing the company's potential for a valuation re-rating, fueled by its recent revenue growth, expansion of testing capacity, and a relatively small market cap that amplifies volatility.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber Technologies is trending as investors digest a flurry of strategic partnerships and institutional accumulation, with recent filings showing heavy buying from prominent hedge funds. The community is actively debating the company's valuation versus its long-term potential in autonomous vehicle integration and travel, while closely monitoring technical price levels ahead of upcoming earnings.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is witnessing heightened volatility and intense social media debate, driven by a combination of macroeconomic inflationary pressures, geopolitical concerns, and emerging industrial demand for silver in AI data center infrastructure. The community is sharply divided between "stackers" who view recent price dips as a strategic buying opportunity and skeptics who interpret the erratic price action as evidence of market manipulation and the conclusion of the recent bullish trend.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing significant investor attention as market participants weigh strong travel demand against the escalating geopolitical risks in the Middle East and rising jet fuel costs. The community is actively debating whether the airline's premium-focused strategy and operational resilience can effectively buffer the margin pressures currently weighing on the broader airline sector.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending as investors react to potential federal initiatives aimed at forcing hyperscalers to fund massive new power capacity, with community sentiment split between viewing this as a long-term growth catalyst for infrastructure providers and expressing frustration over recent price volatility. Discussion is heavily focused on the stock's position as a core 'AI power' play, with many participants looking for buying opportunities during pullbacks and highlighting institutional confidence in the company's ability to supply the grid.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trending as investors grapple with a bond market selloff, evidenced by the 30-year Treasury yield hitting 5% amid persistent inflationary concerns and high U.S. debt levels. The community remains deeply divided, with some betting on a "buy-and-hold" strategy at historic lows while others argue the sector remains "uninvestable" due to rising yields and an evolving Fed landscape.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending following a better-than-expected quarterly earnings report where the company beat estimates and raised its full-year guidance, signaling improved momentum from store revamps and strategic growth initiatives. The community is actively debating whether this performance marks a sustainable turnaround or a temporary relief bounce, while also closely watching broader retail sector trends and potential impacts from macroeconomic headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Tonmya is the first U.S. Food and Drug Administration-approved treatment for fibromyalgia in adults in more than 15 years.</li><li>The drug is a non-opioid therapy for daily bedtime use to manage chronic pain.</li><li>Investors are also focusing on TNX-4800, Tonix’s antibody to prevent Lyme disease.</li></ul>Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) drew strong retail interest on Wednesday, rising about 7% after the company announced a new agreement with a major group purchasing organization to broaden access to its fibromyalgia treatment.Fibromyalgia is a chronic pain condition affecting mostly women, marked by widespread pain, fatigue, poor sleep, and cognitive and mood issues.<h2 class="st-heading-2">TNXP Bets Big On Tonmya</h2>The deal opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S. Tonmya, launched in November 2025, is the first U.S. Food and Drug Administration (FDA) approved treatment for fibromyalgia in adults in more than 15 years. It is a non-opioid therapy for daily bedtime use to manage chronic pain over the long term.The agreement marks steady progress in Tonix’s push to broaden patient access. The company is also advancing discussions with Medicare and Medicaid.“Fibromyalgia patients have experienced dissatisfaction with available therapies, with 85% of first-line treatments failing due to efficacy and tolerability issues. We are committed to providing patient access to Tonmya by continuing to engage with commercial payers on its value and offering a patient support program to help patients access their prescribed medication,” said Seth Lederman, President and CEO.<h2 class="st-heading-2">Lyme Disease Treatment Also In Focus</h2>Investors are also focusing on TNX-4800, Tonix’s long-acting antibody to prevent Lyme disease. The company plans to begin a Phase 2 randomized, double-blind, placebo-controlled field study. It is expected to test a two-dose regimen, with an initial injection in spring followed by a booster in summer.The main goal is to evaluate protection against Lyme disease over a six-month period. Tonix expects to have study drug supply ready in early 2027, with further testing, including a human challenge study, planned for 2028.<h2 class="st-heading-2">TNXP: How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/TNXP">TNXP</a> on Stocktwits turned ‘extremely bullish’ from bullish’ a day earlier, while message volumes remained ‘high.’One user said the latest partnership could add at least $30 million in annual revenue.<stembedurl>https://stocktwits.com/Pipipopopipi/message/652420353</stembedurl>However, another user expressed disappointment that the stock couldn’t break $15, given the “huge announcement.”<stembedurl>https://stocktwits.com/StockJayC/message/652434435</stembedurl>The stock has declined more than 16% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-rising-novavax-royalties-growth-pfizer-deal/cZQz4flReOR">Novavax Tops Expectations On High-Margin Deals – Retail Says ‘It’s The Only Thing That Matters’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Climbs 7%: Retail Bets On $30M Revenue Upside From Tonmya Deal

The company announced a new agreement with a major group purchasing organization which opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S.

Why TNXP Stock Is Suddenly Back On Retail Radar

Equity

Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.read more...

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD Cowen

TD Cowen raised Tonix Pharmaceuticals to a "strong-buy" rating in a report on Tuesday...

Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-tonix-pharmaceuticals-holding-corp-stock...

<ul class="summary-bullets"><li>Overall net revenue from sales in Q1 was $8.3 million, the company said.&nbsp;</li><li>The company said that it now has funds to sustain itself till the second quarter of 2027.</li><li>Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million. &nbsp;</li></ul> Shares of Tonix Pharmaceuticals (TNXP) fell 3% after hours after the company said that it expects a wider preliminary net loss for the first quarter of 2026 and revenue of $3.7 million for its newly launched drug Tonmya.The company said on Friday that it expects a Q1 net loss of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.<h2 class="st-heading-2">TNXP’s Preliminary Numbers</h2>Q1 net revenue from sales of its treatments Zembrace SymTouch, and Tosymra for the quarter ended March 31, 2026, was approximately $3.2 million, compared to $2.4 million for the quarter ended March 31, 2025.Net revenue from sales of Tonmya for the quarter was approximately $3.7 million. Tonmya, an FDA-approved, non-opioid medication designed to treat fibromyalgia in adults, was launched in November 2025.Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million, Tonix said. &nbsp;The company said that it ended the first quarter with about $185.5 million in cash and cash equivalents, which, together with net proceeds of $17.4 million that it raised in April 2026 to be enough to sustain it till the second quarter of 2027.The company is now slated to report its full financial results on May 11.<h2 class="st-heading-2">How Did TNXP Retail Traders React?</h2>On Stocktwits, retail sentiment around TNXP stock stayed in the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user opined that the numbers put forth by Tonix are being “misunderstood” and Tonmya launch is not “as weak as it appears.”<stembedurl>https://www.stocktwits.com/ltinvestorx/message/652073834</stembedurl>Another user opined that the company entered 2026 with real momentum and a stronger balance sheet than many of its small-cap biotech peers.<stembedurl>https://www.stocktwits.com/ACMTrader/message/652072480</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> fell 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/celc-stock-jumps-after-hours-on-positive-breast-cancer-trial-update/cZQ8HuEReeM">CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug

The company said on Friday that it now expects a net loss for the first quarter of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.

Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell

Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from...

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Investors are expressing intense frustration over ongoing ATM share sales and the impact of continued dilution on shareholder value.

The community is closely tracking TONMYA prescription volumes and GPO access as the key metric for potential Q2 commercial success.

Bullish investors are highlighting recent 13G filings and increased holdings by major funds as a sign of confidence despite the price slide.

Debate surrounds the widening gap between surging revenue and rising operational expenses as the company navigates its expensive product launch.

Current Price	$15.74
Prev Close	$14.09
Open	$13.71
Dividend Yield	0.00%
50-Day Moving Average	$13.69
Beta	1.36
Avg. Volume	390,760.08
PE Ratio	-0.98

52-Week High	$69.97
52-Week Low	$11.60
Market Capitalization	$224.61M
EPS (Annual)	-$14.57
Price to Book	0.88
Revenue Per Employee	$92,302.82

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp